ADVANCED NON-SMALL CELL LUNG CANCER
Clinical trials for ADVANCED NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets tough lung cancers in first human trial
Disease control Recruiting nowThis study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill targets HER2 lung cancer in major trial
Disease control Recruiting nowThis Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could your own tumor cells beat lung cancer? new trial tests it
Disease control Recruiting nowThis study takes white blood cells from a patient's lung tumor, grows them in large numbers in the lab, and gives them back to the patient to fight the cancer. The goal is to see if these specially selected cells can shrink tumors in people with advanced non-small cell lung cance…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for hard-to-treat lung cancer: targeted drug plus immunotherapy tested
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for rare lung cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New lung cancer combo aims to beat current standard
Disease control Recruiting nowThis study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for Hard-to-Treat lung cancer: expanded access to targeted pill
Disease control AVAILABLEThis program offers oral sevabertinib to adults with advanced non-small cell lung cancer that has a specific HER2 gene change and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be in good enough health to take oral me…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Lighter chemo, same punch? new combo aims to spare older lung cancer patients harsh side effects
Disease control Recruiting nowThis study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to sto…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo therapy aims to halt ALK-Positive lung cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding local treatments (like radiation or surgery) to the drug lorlatinib can better control advanced ALK-positive non-small cell lung cancer. About 30 patients who have not had prior targeted therapy will receive lorlatinib for 12 weeks, then ma…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for Hard-to-Treat lung cancer: targeted drug combo enters human trials
Disease control Recruiting nowThis study tests two new drug combinations for people with advanced non-small cell lung cancer that has a HER2 mutation. The drugs are SHR-A1811 (given by IV) combined with either pyrotinib (a pill) or SHR-1316 (another IV drug). The trial has two parts: first, finding the safest…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Could clearing lung bacteria boost cancer treatment?
Disease control Recruiting nowThis early-phase trial tests whether adding two inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab can help treat advanced non-small cell lung cancer (NSCLC). The idea is that harmful bacteria in the lungs may help tumors grow, so clearing th…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New smart drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy targets tough lung cancers
Disease control Recruiting nowThis early-stage study tests a new drug combination (JSKN016 plus other treatments) in 288 people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The main goals are to see if the treatment shrinks tumors and to check for side effects. Th…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for brain metastases? drug duo targets advanced cancers
Disease control Recruiting nowThis study tests whether combining two drugs, niraparib and dostarlimab, can control advanced cancers that have spread to the brain. It includes 120 adults with certain cancer types like BRCA-mutated or lung cancers. The goal is to see if the treatment shrinks or stabilizes brain…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New smart drug TQB6411 targets two cancer proteins in early human trial
Disease control Recruiting nowThis Phase 1 trial tests TQB6411, an antibody-drug conjugate designed to bind to EGFR and c-Met proteins on tumor cells, blocking their growth signals and releasing a toxin to kill the cells. The study will enroll 216 adults with advanced malignant tumors to find the safest dose …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo shows promise for tough lung cancer
Disease control Recruiting nowThis study tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has not been treated before. About 240 adults will take part to see if the drug shrinks tumors and how safe it is. The goal is to f…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for rare lung cancer: targeted pill tepotinib faces final test
Disease control Recruiting nowThis Phase 3 trial is testing whether the targeted drug tepotinib works better than standard treatments for people with advanced non-small cell lung cancer that has a specific genetic change (MET exon 14 mutation). About 133 patients who have already tried at least one prior trea…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Breathing and exercise program may boost survival in advanced lung cancer
Symptom relief Recruiting nowThis study tests whether a 12-session pulmonary rehabilitation program—including breathing exercises, resistance training, and treadmill walking—can help patients with advanced non-small-cell lung cancer maintain muscle mass, improve lung function, and reduce inflammation. The go…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: NA • Sponsor: Instituto Nacional de Cancerologia de Mexico • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
AI could predict who lives longer after lung cancer immunotherapy
Knowledge-focused Recruiting nowThis study looks back at 600 advanced lung cancer patients who received immunotherapy. Researchers will analyze their tissue samples and genetic data to find patterns linked to long-term survival. They aim to build an AI model that can predict survival from standard microscope im…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
Knowledge-focused Recruiting nowThis study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Sponsor: BeOne Medicines • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could your muscle mass change how chemo works?
Knowledge-focused Recruiting nowThis study looks at how a person's fat-free mass (like muscle) affects the dose and side effects of the chemotherapy drug carboplatin in patients with advanced non-small cell lung cancer. Researchers will track 132 patients to see if body composition is linked to toxicity. The go…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Sponsor: Instituto Nacional de Cancerologia de Mexico • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC